Patrick Y. Wen

Active 1990–2026

Also published as
Patrick Y Wen
441
Papers
81,000
Citations
148
h-index
418
i10-index

Citations

Citations per year for Patrick Y. Wen1983: 1 citations1985: 1 citations1990: 1 citations1991: 10 citations1992: 18 citations1993: 15 citations1994: 18 citations1995: 27 citations1996: 17 citations1997: 24 citations1998: 41 citations1999: 42 citations2000: 72 citations2001: 63 citations2002: 62 citations2003: 79 citations2004: 73 citations2005: 76 citations2006: 107 citations2007: 163 citations2008: 231 citations2009: 408 citations2010: 517 citations2011: 649 citations2012: 544 citations2013: 527 citations2014: 597 citations2015: 598 citations2016: 545 citations2017: 728 citations2018: 710 citations2019: 2,303 citations2020: 3,249 citations2021: 3,233 citations2022: 2,999 citations2023: 2,636 citations2024: 4,405 citations2025: 2,308 citations2026: 103 citations1984: no citations, so this year is not shown1986–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,868 citing papers, 28.2% of this breakdownChina: 3,888 citing papers, 13.9% of this breakdownGermany: 1,831 citing papers, 6.5% of this breakdownUnited Kingdom: 1,331 citing papers, 4.8% of this breakdownItaly: 1,322 citing papers, 4.7% of this breakdownFrance: 1,011 citing papers, 3.6% of this breakdownCanada: 926 citing papers, 3.3% of this breakdownNetherlands: 890 citing papers, 3.2% of this breakdownSwitzerland: 770 citing papers, 2.8% of this breakdownSpain: 677 citing papers, 2.4% of this breakdownJapan: 621 citing papers, 2.2% of this breakdownSouth Korea: 547 citing papers, 2% of this breakdown
0%28.2%Other 22.4%

Fields

  • Medicine63%
  • Biochemistry, Genetics and Molecular Biology22.2%
  • Immunology and Microbiology5.3%
  • Neuroscience3.2%
  • Engineering1.9%
  • Materials Science1.5%
  • Other2.9%

Topics

  • Glioma Diagnosis and Treatment13.3%
  • Brain Metastases and Treatment5.4%
  • Radiomics and Machine Learning in Medical Imaging2.6%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Meningioma and schwannoma management2.4%
  • Cancer, Hypoxia, and Metabolism2.1%
  • Other71.6%

Coauthors

All papers

Open in search
  1. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Taphoorn, Joerg-Christian Tonn, Jonathan Tsang, Roel G.W. Verhaak, Andreas von Deimling, Wolfgang Wick, Gelareh Zadeh, David A. Reardon, Kenneth Aldape, Martin J. van den Bent - Neuro-Oncology 2020 cited by 1,137

  2. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 719

  3. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heather Daley, Patrick Y. Wen, E. Antonio Chiocca, Maegan Harden, Niall J. Lennon, Stacey Gabriel, Gad Getz, Eric S. Lander, Aviv Regev, Jerome Ritz, Donna Neuberg, Scott J. Rodig, Keith L. Ligon, Mario L. Suvà, Kai W. Wucherpfennig, Nir Hacohen, Edward F. Fritsch, Kenneth J. Livak, Patrick A. Ott, Catherine J. Wu, David A. Reardon - Nature 2018 cited by 1,464

  4. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2019 cited by 1,387

  5. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 cited by 3,829

  6. Glioma

    Authors: , , , , , , , , , , - Nature Reviews Disease Primers 2015 cited by 1,149

  7. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 462

  8. Malignant Gliomas in Adults

    Authors: , - New England Journal of Medicine 2008 cited by 4,241

  9. Clinical trial links oncolytic immunoactivation to survival in glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott J. Rodig, Patrick Y. Wen, Eudocia Q. Lee, Lakshmi Nayak, Ugonma Chukwueke, L. Nicolas Gonzalez Castro, Sydney Dumont, Tracy T. Batchelor, Kara A. Kittelberger, Ekaterina Tikhonova, Natalia Miheecheva, D Tabakov, Nara Shin, Alisa M. Gorbacheva, Artemy Shumskiy, Felix Frenkel, Estuardo Aguilar-Córdova, Laura K. Aguilar, David Krisky, James Wechuck, Andrea G. Manzanera, Christopher Matheny, Paul P. Tak, Francesca Barone, Daniel Kovarsky, Itay Tirosh, Mario L. Suvà, Kai W. Wucherpfennig, Keith L. Ligon, David A. Reardon, E. Antonio Chiocca - Nature 2023 cited by 256

  10. Mechanisms and therapeutic implications of hypermutation in gliomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maïté Verreault, Marine Giry, Erell Guillerm, Samy Ammari, Frédéric Beuvon, Karima Mokhtari, Agustí Alentorn, Caroline Dehais, Caroline Houillier, Florence Laigle–Donadey, Dimitri Psimaras, Eudocia Q. Lee, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Alexandre Carpentier, Philippe Cornu, Laurent Capelle, Bertrand Mathon, Jill S. Barnholtz‐Sloan, Arnab Chakravarti, Wenya Linda Bi, E. Antonio Chiocca, Katie Fehnel, Sanda Alexandrescu, N. Susan, Daphne A. Haas‐Kogan, Tracy T. Batchelor, Garrett M. Frampton, Brian M. Alexander, Raymond Y. Huang, Azra H. Ligon, Florence Coulet, Jean‐Yves Delattre, Khê Hoang‐Xuan, David M. Meredith, Sandro Santagata, Alex Duval, Marc Sanson, Andrew D. Cherniack, Patrick Y. Wen, David A. Reardon, Aurélien Marabelle, Peter J. Park, Ahmed Idbaïh, Rameen Beroukhim, Pratiti Bandopadhayay, Franck Bielle, Keith L. Ligon - Nature 2020 cited by 720

  11. Response assessment criteria for brain metastases: proposal from the RANO group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 1,088

  12. Glioma

    Authors: , , , , , , - Nature Reviews Disease Primers 2024 cited by 492

  13. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 cited by 298

  14. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

    Authors: , , , , , , , , , , , , , , , , , - Neuro-Oncology 2015 cited by 580

  15. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study

    Authors: , , , , , , , , , , , , - Neuro-Oncology 2017 cited by 838

  16. Epidemiology of Brain Metastases

    Authors: , , - Current Oncology Reports 2011 cited by 1,372

  17. Molecular targeted therapy of glioblastoma

    Authors: , , , , , , , - Cancer Treatment Reviews 2019 cited by 724

  18. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 518

  19. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrick Y. Wen - Neuro-Oncology 2022 cited by 237

  20. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 353

  21. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 885

  22. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 257

  23. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours

    Authors: , , , - Nature Reviews Neurology 2022 cited by 298

  24. Epidemiology of brain metastases and leptomeningeal disease

    Authors: , , - Neuro-Oncology 2021 cited by 384